Personalized gene editing became real enough to regulate around.
The Baby KJ case showed that patient-specific in vivo editing can be designed and delivered rapidly, while exposing the need for reusable regulatory logic.
Rare DiseasesSmall populationsNatural historyN-of-1
Rare Diseases
As of June 2026, rare diseases are moving toward mechanism-specific evidence packages. Natural history, novel endpoints, patient-specific gene editing, platform prior knowledge, and variant-to-rescue models are becoming as important as molecule choice. The hard question is what evidence is enough when conventional trials are impossible.
Domain research lens
This page tracks rare-disease development gates: natural-history quality, surrogate endpoint credibility, N-of-1 feasibility, variant interpretation, rescue evidence, and platform reuse.
June 2026 field state
A field where evidence design is the product strategy.
The strongest rare-disease programs treat genotype, phenotype, natural history, endpoint, manufacturing, and platform knowledge as one coupled decision system.
Small-population development, monogenic and mitochondrial disease, natural history, surrogate endpoints, variant interpretation, N-of-1 therapies, and evidence flexibility.
The domain thesis: rare-disease value is created when a tiny population can still produce a transparent, mechanistic, and decision-grade evidence package.
Endpoints are becoming explicit development objects.
FDA's RDEA program and surrogate-endpoint workshops make endpoint construction part of rare-disease strategy.
Association is not rescue.
Variant calls, omics predictions, and biomarker movement need functional rescue and patient-relevant endpoints before they justify intervention.
Recent research signals
The 2025-2026 update is a decision-gate wave.
Each signal below starts from the field: what changed, why it matters, and which research or buyer decision becomes more testable.
A patient-specific in vivo editing case reset expectations.
A NEJM report described patient-specific in vivo gene editing for an infant with a rare genetic disease, supported by NIH-linked platform work.
Why it matters
The case makes bespoke therapy plausible while forcing questions about safety, manufacturing, economics, follow-up, and reuse of prior knowledge.
Decision implication
Changes rare-disease strategy from single-asset development to platform-plus-evidence routing.
FDA is focusing rare-disease surrogate endpoint evidence.
FDA convened a May 2026 workshop on novel surrogate endpoints for rare disease drug development.
Why it matters
Small populations need endpoint credibility that connects mechanism, biomarker, clinical meaning, and treatment effect.
Decision implication
Changes whether a program can use a biomarker as a development gate or an approval-relevant endpoint.
Platform evidence reuse became a regulatory design question.
FDA's June 2026 draft guidance on leveraging prior knowledge for genome-editing gene therapy products points toward structured reuse of platform evidence.
Why it matters
Rare diseases cannot afford redundant full evidence stacks for every tiny population if platform similarity is credible.
Decision implication
Changes the build decision for modular gene therapy and editing programs.
Natural history remains the rare-disease evidence backbone.
FDA rare-disease guidance emphasizes natural-history study design and its role in safe and effective development.
Why it matters
Without a reliable untreated trajectory, a biomarker, endpoint, or single-arm response can be impossible to interpret.
Decision implication
Changes whether the next investment should be therapy, registry, endpoint, or rescue model.
What leading groups are working on
The current edge is a set of validation programs, not a single breakthrough story.
These representative programs and research fronts frame the active field before the page maps Zemi Dossiers into it.
Bespoke editing
Patient-specific in vivo gene editing as a real precedent
The Baby KJ case shows that a rare-disease therapy can be designed, manufactured, and delivered around one patient's variant, while exposing safety, cost, reuse, and follow-up questions.
Endpoint scienceNovel surrogate endpoints become development objects
FDA's 2026 rare-disease surrogate endpoint workshop puts mechanistic, translational, clinical, and methodological evidence at the center of approval strategy.
Natural historyUntreated trajectories as the evidence backbone
Natural-history study design determines whether single-arm change, external controls, biomarker movement, or patient-reported outcomes can be interpreted.
Platform reusePrior knowledge for modular gene therapy and editing
Rare populations benefit most when prior platform evidence can be reused without hiding target-, tissue-, or patient-specific risks.
Variant-to-rescueMoving from annotation to functional rescue
AI and multi-omics systems are valuable only when variant calls become perturbation experiments, rescue models, and patient-relevant endpoints.
Decision gates
What must be true before a buyer should build, fund, partner, monitor, avoid, or run the next study.
These are field-level gates first. The dossier library appears later as the set of existing Zemi products that can help investigate them.
Natural history
Is the untreated trajectory known well enough to interpret change?
Variant causality
Does the variant cause the phenotype, and can rescue be shown?
Endpoint credibility
Does the endpoint reflect function, survival, irreversible morbidity, or patient benefit?
Platform bridging
Which prior evidence can be reused without hiding new risks?
Manufacturing feasibility
Can the therapy be made fast enough and consistently enough for tiny populations?
Follow-up burden
How will durability, off-target, immune, and developmental risks be monitored?
Zemi Dossiers in this domain
The dossiers sit where new research creates hard buyer decisions.
Each dossier card uses stats from the actual research report manifest and Evidence & Decision Workbook, including pages, workbook sheets, evidence/source rows, claim rows, power rows, and decision instruments where present.
Primary Zemi Dossier
AI Multi-Omics Variant-to-Rescue
Routes variant interpretation toward rescue experiments instead of stopping at association, prediction, or annotation confidence.
Why it belongs here
Which variant-to-function programs have enough evidence to justify rescue experiments, and what readout would falsify the rescue thesis?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Primary Zemi Dossier
Mitochondrial Medicine Permanence Ladder
Maps mitochondrial interventions onto a permanence ladder so buyers do not overbuild or underbuild the required correction.
Why it belongs here
Which mitochondrial programs need transient support, durable shift, editing, replacement, or avoidance based on heteroplasmy and tissue constraints?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Immune Aging Supply Chain
Routes immune-aging programs to the binding supply-chain node before treating broad immune decline as one therapeutic target.
Why it belongs here
Which immune-aging interventions target the binding node, and when would restoration create more risk than resilience?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
In Vivo Gene Editing
Turns in-vivo editing from a modality story into a coupled-system failure-mode map.
Why it belongs here
Which in-vivo editing programs are limited by edit chemistry, delivery, immune response, durability, or CMC before pivotal spend?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
RNA Editing & the Permanence Spectrum
Positions RNA editing on a permanence spectrum so buyers do not confuse reversibility with durability or safety by default.
Why it belongs here
Which RNA-editing programs should rent correction, extend correction, or avoid RNA-level strategy based on permanence needs?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Epigenome Editing & Tunable Permanence
Classifies whether mitotic dilution, active erasure, or reactivation pressure will dominate before buyers commit to delivery, indication, or permanence strategy.
Why it belongs here
Which epigenome-editing programs have a defensible durability strategy, and what decay force would erase the imposed mark before benefit is proven?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Genetic Cardiomyopathy Precision Therapies
Uses molecular mechanism rather than gene label to route programs toward addition, knockdown, editing, or avoidance logic.
Why it belongs here
Which genetic cardiomyopathy programs match mechanism, modality, delivery, safety window, and evidentiary standard well enough to advance?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Watchlist
Signals that would change the map in 2026-2028.
These are the developments most likely to change the field map, evidence posture, or next-study priorities.
RDEA
FDA RDEA acceptances and public endpoint case studies
Public endpoint examples would clarify what evidence turns a rare biomarker into an approval-relevant measure.
N-of-1 editingBaby KJ follow-up and successor bespoke-editing programs
Durability, immune effects, developmental follow-up, and repeatability will decide whether the precedent becomes a platform.
Functional genomicsVariant-to-rescue platforms that close prediction to phenotype rescue
Prediction alone will not carry rare-disease decisions unless it points to an intervention that rescues a disease-relevant model.
Mitochondrial medicineSurrogate endpoints tied to function
Mitochondrial programs need tissue-specific measures that connect energy biology to fatigue, organ function, development, or survival.
Field-note discipline
Current-state pages need a source-aware update layer.
The public page stays readable, but the underlying domain model tracks source-linked developments that change evidence posture, buyer decisions, or next-study priorities.
2025 / Personalized editing
Bespoke therapy changes the evidence question.
The field must decide what can be standardized when the product, variant, and patient may all be unique.
2026 / Endpoints Rare-disease endpoint construction is now a strategic asset.Natural history, mechanism, biomarker sensitivity, and patient-relevant function need to be built together.
2026 / Platform evidence Prior knowledge is useful only when similarity is explicit.Modular rare-disease programs should state which evidence is reusable and which risks are newly introduced.
From domain signal to Zemi Dossier
Request access to inspect the full research report, Evidence & Decision Workbook, power calculations, and release-audit surfaces behind each decision package.